+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil



Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil



Genetic Testing and Molecular Biomarkers 17(11): 799-806



Limited studies indicate a possible association of 5'-UTR thymidylate synthase enhancer region polymorphism and treatment outcome in patients medicated with 5-fluorouracil (5-FU). The study was designed to verify the relationship in patients with colorectal cancer (CRC), a Polish population that received 5-FU-based adjuvant chemotherapy. The study analyzed 145 Astler-Coller B2 and C CRC patients. Genotyping for a variable number of tandem repeats and G to C single-nucleotide polymorphism in the 5'-UTR of the thymidylate synthase (TS) gene was carried out. TS genotypes were classified into high expression (high TS) and low expression types (low TS). High TS was found in 22.8% of patients. The right-side tumors were more frequently associated with high TS than the left-side tumors (p=0.024). High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042). Disease-free survival after 20 months (DFS 20) was longer in subjects with low TS than in high TS (p=0.043). Patients who underwent chemotherapy had longer DFS 20 in the low TS than in the high TS subgroup (p=0.051). The low TS was found to be an independent good prognostic factor for DFS 20 in the whole group as well as in the subgroup treated with chemotherapy (p=0.024 and p=0.034, respectively). Patients with low TS did not show any differences in DFS 20 whether they were treated with adjuvant chemotherapy or not. Proximal CRC tumors are characterized by higher TS expression genotypes than distal tumors, and are at significantly greater risk of early recurrence during the first 20 months after surgery.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056577601

Download citation: RISBibTeXText

PMID: 23968134

DOI: 10.1089/gtmb.2013.0171


Related references

Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenetics and Genomics 15(10): 723-730, 2005

Thymidylate synthase quantitation predicts for disease-free survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Proceedings of the American Association for Cancer Research Annual Meeting 42: 618, 2001

Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. Journal of Surgical Oncology 101(1): 22-27, 2010

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clinical Cancer Research 9(11): 4116-4124, 2003

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clinical Cancer Research 10(17): 5880-5888, 2004

Thymidylate synthase and dihydropyrimidine dehydrogenase expression in stage II and III colorectal cancer patients receiving adjuvant 5-fluorouracil. European Journal of Cancer 37(Supplement 6): S300-S301, 2001

Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anti-Cancer Drugs 18(7): 821-825, 2007

Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil. British Journal of Cancer 86(8): 1365, 22 April, 2002

Reply Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil. British Journal of Cancer 86(8): 1366, 22 April, 2002

Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. Journal of Clinical Oncology 24(10): 1603-1611, 2006

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70(5): 366-377, 2006

Predictive significance of thymidylate synthase and dihydropyrimidine dehydrogenase levels in patients with completely resected colorectal cancer receiving adjuvant 5-fluorouracil therapy. Journal of Clinical Oncology 23(16_suppl): 3629-3629, 2016

Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology 67(2): 135-142, 2004

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. British Journal of Cancer 85(6): 827-830, 2001

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. Journal of Clinical Oncology 19(23): 4298-4304, 2001